CBR1

Summary

CBR1 (carbonyl reductase 1, HGNC:1548) is a protein-coding gene on chromosome 21q22.12, encoding Carbonyl reductase [NADPH] 1 (P16152). NADPH-dependent reductase with broad substrate specificity.

The protein encoded by this gene belongs to the short-chain dehydrogenases/reductases (SDR) family, which function as NADPH-dependent oxidoreductases having wide specificity for carbonyl compounds, such as quinones, prostaglandins, and various xenobiotics. Alternatively spliced transcript variants have been found for this gene.

Source: NCBI Gene 873 — RefSeq curated summary.

At a glance

• GWAS associations: 4
• Clinical variants (ClinVar): 67 total — 2 pathogenic
• Druggable target: yes — 1 molecules with ChEMBL bioactivity
• MANE Select transcript: NM_001757

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:1548
Approved symbol	CBR1
Name	carbonyl reductase 1
Location	21q22.12
Locus type	gene with protein product
Status	Approved
Aliases	SDR21C1
Ensembl gene	ENSG00000159228
Ensembl biotype	protein_coding
OMIM	114830
Entrez	873

Gene structure

Transcript identifiers

Ensembl transcripts: 5 — 4 protein_coding, 1 protein_coding_CDS_not_defined

ENST00000290349, ENST00000399191, ENST00000439427, ENST00000466328, ENST00000530908

RefSeq mRNA: 2 — MANE Select: NM_001757 NM_001286789, NM_001757

CCDS: CCDS13641, CCDS68202

Canonical transcript exons

ENST00000290349 — 3 exons

Exon	Start	End
ENSE00001044162	36072446	36073164
ENSE00003643969	36070950	36071057
ENSE00003846386	36070024	36070404

Expression profiles

Bgee: expression breadth ubiquitous, 281 present calls, max score 99.23.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 86.3618 / max 1274.4562, expressed in 1759 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
188976	86.3618	1759

Top tissues by expression

293 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
jejunal mucosa	UBERON:0000399	99.23	gold quality
duodenum	UBERON:0002114	98.71	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	98.70	gold quality
corpus callosum	UBERON:0002336	98.46	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	98.01	gold quality
spinal cord	UBERON:0002240	97.97	gold quality
right adrenal gland	UBERON:0001233	97.73	gold quality
right adrenal gland cortex	UBERON:0035827	97.58	gold quality
caudate nucleus	UBERON:0001873	97.56	gold quality
esophagus mucosa	UBERON:0002469	97.54	gold quality
putamen	UBERON:0001874	97.52	gold quality
small intestine Peyer’s patch	UBERON:0003454	97.26	gold quality
mucosa of transverse colon	UBERON:0004991	97.22	gold quality
amygdala	UBERON:0001876	97.20	gold quality
left adrenal gland	UBERON:0001234	97.12	gold quality
right lobe of liver	UBERON:0001114	97.08	gold quality
metanephros cortex	UBERON:0010533	97.00	gold quality
nucleus accumbens	UBERON:0001882	96.96	gold quality
skin of leg	UBERON:0001511	96.89	gold quality
small intestine	UBERON:0002108	96.89	gold quality
skin of abdomen	UBERON:0001416	96.83	gold quality
inferior vagus X ganglion	UBERON:0005363	96.83	gold quality
left adrenal gland cortex	UBERON:0035825	96.62	gold quality
substantia nigra	UBERON:0002038	96.54	gold quality
right frontal lobe	UBERON:0002810	96.49	gold quality
lateral globus pallidus	UBERON:0002476	96.48	gold quality
prefrontal cortex	UBERON:0000451	96.38	gold quality
body of stomach	UBERON:0001161	96.38	gold quality
stromal cell of endometrium	CL:0002255	96.35	gold quality
midbrain	UBERON:0001891	96.26	gold quality

Single-cell (SCXA)

Detected in 8 experiment(s), a significant marker in 7.

Experiment	Marker?	Max mean expression
E-GEOD-125970	yes	902.53
E-GEOD-81383	yes	465.01
E-CURD-114	yes	70.59
E-HCAD-11	yes	23.38
E-HCAD-1	yes	20.82
E-GEOD-84465	yes	12.85
E-MTAB-6524	no	269.97
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): AHR, NFE2L2

miRNA regulators (miRDB)

76 targeting CBR1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-5193	100.00	67.26	1744
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-1184	99.99	68.19	1458
HSA-MIR-335-3P	99.93	73.36	4958
HSA-MIR-153-5P	99.89	73.86	6317
HSA-MIR-3065-3P	99.87	70.25	1407
HSA-MIR-6756-5P	99.82	67.97	2466
HSA-MIR-3133	99.81	70.92	3506
HSA-MIR-320A-3P	99.77	69.73	2107
HSA-MIR-320B	99.77	69.73	2107
HSA-MIR-320C	99.77	69.73	2107
HSA-MIR-320D	99.77	69.73	2107
HSA-MIR-4429	99.77	69.62	2111
HSA-MIR-7856-5P	99.75	69.99	2901
HSA-MIR-1976	99.74	65.48	1127
HSA-MIR-4524A-3P	99.72	66.85	2406
HSA-MIR-378G	99.71	64.90	1106
HSA-MIR-3059-5P	99.70	69.93	2491
HSA-MIR-6766-5P	99.68	67.70	2325
HSA-MIR-6762-3P	99.66	66.94	1188
HSA-MIR-12123	99.52	71.79	2990
HSA-MIR-5007-3P	99.51	68.14	1242
HSA-MIR-6081	99.48	66.07	1446
HSA-MIR-942-5P	99.41	68.40	1977
HSA-MIR-548B-3P	99.38	67.26	1000
HSA-MIR-1206	99.30	69.32	1016
HSA-MIR-7158-5P	99.25	67.95	796
HSA-MIR-146A-3P	99.13	68.99	1881
HSA-MIR-452-3P	99.01	66.25	1241
HSA-MIR-1909-5P	98.94	64.01	484

Literature-anchored findings (GeneRIF, showing 38)

• the functional genetic determinant of CBR1 activity toward relevant physiological and pharmacological substrates (PMID:17344335)
• The functional characterization of the promoter of CBR1 is reported. (PMID:17569794)
• Carbonyl reductase-1 (CBR1), microsomal prostaglandin E synthase-1 and 2 (mPGES-1, mPGES-2), cytosolic prostaglandin E synthase (cPGES), aldoketoreductase (AKR1C1) and prostaglandin F synthase (AKR1C3) were all expressed in hair follicles. (PMID:17697149)
• These results suggested that hCBR3 and hCBR1 play distinct physiological roles. (PMID:18493841)
• Human carbonyl reductase 1 is an S-nitrosoglutathione reductase (PMID:18826943)
• CBR1 polymorphisms have a significant influence on the pharmacokinetics of doxorubicin in Asian breast cancer patients. (PMID:19016765)
• the nonsynonymous single nucleotide polymorphisms generating mutations OF CBR1 may alter bioavailability of anthracyclines in cancer patients (PMID:19204081)
• analysis of the structural basis for substrate specificity in human monomeric carbonyl reductases CBR1 (PMID:19841672)
• This protein has been found differentially expressed in thalami from patients with schizophrenia. (PMID:20471030)
• a physiological role of CBR1, but not for CBR3, in S-nitrosoglutathione reduction and thus ultimately in regulation of NO signaling (PMID:21256830)
• Polymorphisms in CBR1 gene did not increase risk of cardiomyopathy after anthracycline treatment of childhood cancers. (PMID:22124095)
• A protein encoded by this locus was found to be differentially expressed in postmortem brains from patients with atypical frontotemporal lobar degeneration. (PMID:22360420)
• CBR1 regulates cancer cell invasion in endometrial adenocarcinomas by regulating the epithelial mesenchymal transition (PMID:22542806)
• This pilot study suggests that CBR1 RNA expression may be helpful in identifying AML patients at risk of developing resistance or toxicity to daunorubicin due to increased formation of daunorubicinol. (PMID:22562609)
• regulation of human CBR1 expression by hsa-miR-574-5p and hsa-miR-921 depends upon rs9024 genotype status (PMID:23133646)
• Nrf2 is a novel transcriptional regulator of CBR1 genes in humans. (PMID:23247010)
• GSNO-induced covalent modification of cysteine residues affects the kinetic mechanism of CBR1. (PMID:23295225)
• we suggest that PEP-1-CBR1 protein may be a therapeutic agent for the treatment of ischemic injuries as well as oxidative-stress-induced cell damage and death. (PMID:24440593)
• The stimulatory effect of cortisol on CBR1 expression may partly explain the concurrent increases of cortisol and prostaglandin PGF2alpha in human amnion tissue prior to the onset of labor (PMID:24654784)
• Protein products of AKR1C1, AKR1C2, AKR7A3, CYP3A4, and carbonyl reductase (CBR1) were found in tumors and those of AKR1C1, AKR7A3, and CBR1 correlated with their transcript levels. (PMID:25526449)
• Inhibition of CBR1 may increase the efficacy of daunorubicin in cancer tissue. (PMID:25541467)
• CBR1 decreases promoted tumor proliferation and growth as well as invasion and metastasis; CBR1 has potential to become a new candidate for molecular targeting therapy. (PMID:25572536)
• Results demonstrate a trend toward decreased functional expression of selective hepatic reductases in ESRD livers. (PMID:26282591)
• Up-Regulation of Carbonyl Reductase 1 Renders Development of Doxorubicin Resistance in Human Gastrointestinal Cancers (PMID:26328486)
• Critical insights into the substrate selectivity of hCBR1 and the interaction between hCBR1 and glutathione. (PMID:26381805)
• These results suggest that CR1 induces apoptosis by activating the caspase pathway via binding to TNFR1. (PMID:26499922)
• AKR1C3 is the primary enzyme and CBR1 is a minor enzyme responsible for warfarin reduction in human liver cytosol. (PMID:27055738)
• CBR1 is an efficient catalyst for the reduction of glutathionylated aldehydes derived from lipid peroxidation. (PMID:27562619)
• The ability of human carbonyl reductase 1 to efficiently catalyze the reduction of glutathionylated aldehydes derived from lipid peroxidation, that in the case of glutathionylated-4-hydroxyalkanals is associated to the ability to oxidize the hemiacetal hydroxyl group (PMID:28274719)
• Data suggest that fatty acids and acyl-CoAs bind competitively with respect to substrate binding to carbonyl reductase 1 (CBR1), an enzyme involved in first-pass drug metabolism in intestinal mucosa; inhibition of CBR1 by these products of digestion may lead to food-drug interactions. (PMID:28450226)
• These findings suggest that CBR1 generating 20beta-dihydrocortisol is a novel pathway modulating GR activation and providing enzymatic protection against excessive GR activation in obesity. (PMID:28878267)
• This study examined the impact of the functional single nucleotide polymorphism CBR1 rs9024 on the bioactivation of loxoprofen in a collection of human liver samples and tumor cell lines. (PMID:29851133)
• Findings suggest that CBR1 has an important role in DNA damage response through regulation of irradiation-mediated ROS generation causing to regulation of radiosensitivity, and CBR1 inhibition with IR might be a potent therapeutic strategy for head and neck squamous cell carcinoma treatment. (PMID:30376862)
• Dehydrogenase/reductase activity of human carbonyl reductase 1 with NADP(H) acting as a prosthetic group. (PMID:31759632)
• Transcription of carbonyl reductase 1 is regulated by DNA topoisomerase II beta. (PMID:32767399)
• Carbonyl Reductase 1 Attenuates Ischemic Brain Injury by Reducing Oxidative Stress and Neuroinflammation. (PMID:33964000)
• LncRNA MYMLR promotes pituitary adenoma development by upregulating carbonyl reductase 1 via sponging miR-197-3p. (PMID:36206098)
• [Altered expression of 15-hydroxyprostaglandin dehydrogenase in chronic rhinosinusitis with nasal polyps]. (PMID:37905483)

Cross-species orthologs

17 orthologs

Organism	Symbol	Gene ID
danio_rerio	cbr1	ENSDARG00000036587
mus_musculus	Cbr1	ENSMUSG00000051483
mus_musculus	Cbr1b	ENSMUSG00000082815
rattus_norvegicus	Cbr1l3	ENSRNOG00000049693
rattus_norvegicus		ENSRNOG00000073936
drosophila_melanogaster	CG7601	FBGN0027583
drosophila_melanogaster	CG31546	FBGN0051546
drosophila_melanogaster	CG31548	FBGN0051548
caenorhabditis_elegans		WBGENE00000970
caenorhabditis_elegans		WBGENE00000975
caenorhabditis_elegans		WBGENE00000981
caenorhabditis_elegans		WBGENE00000993
caenorhabditis_elegans		WBGENE00008985
caenorhabditis_elegans		WBGENE00008986
caenorhabditis_elegans		WBGENE00011424
caenorhabditis_elegans		WBGENE00022809
caenorhabditis_elegans		WBGENE00219274

Paralogs (13): RDH8 (ENSG00000080511), DHRS7 (ENSG00000100612), DHRS2 (ENSG00000100867), DHRS7B (ENSG00000109016), HSD11B1 (ENSG00000117594), HSDL2 (ENSG00000119471), DHRS4 (ENSG00000157326), DHRS1 (ENSG00000157379), CBR3 (ENSG00000159231), HSD11B1L (ENSG00000167733), DHRS7C (ENSG00000184544), DHRS4L2 (ENSG00000187630), DHRS11 (ENSG00000278535)

Protein

Protein identifiers

Carbonyl reductase [NADPH] 1 — P16152 (reviewed: P16152)

Alternative names: 15-hydroxyprostaglandin dehydrogenase [NADP(+)], 20-beta-hydroxysteroid dehydrogenase, Alcohol dehydrogenase [NAD(P)+] CBR1, NADPH-dependent carbonyl reductase 1, Prostaglandin 9-ketoreductase, Prostaglandin-E(2) 9-reductase, Short chain dehydrogenase/reductase family 21C member 1

All UniProt accessions (4): A0A384NL53, A8MTM1, P16152, E9PQ63

UniProt curated annotations — full annotation on UniProt →

Function. NADPH-dependent reductase with broad substrate specificity. Catalyzes the reduction of a wide variety of carbonyl compounds including quinones, prostaglandins, menadione, plus various xenobiotics. Catalyzes the reduction of the antitumor anthracyclines doxorubicin and daunorubicin to the cardiotoxic compounds doxorubicinol and daunorubicinol. Can convert prostaglandin E to prostaglandin F2-alpha. Can bind glutathione, which explains its higher affinity for glutathione-conjugated substrates. Catalyzes the reduction of S-nitrosoglutathione. In addition, participates in the glucocorticoid metabolism by catalyzing the NADPH-dependent cortisol/corticosterone into 20beta-dihydrocortisol (20b-DHF) or 20beta-corticosterone (20b-DHB), which are weak agonists of NR3C1 and NR3C2 in adipose tissue.

Subunit / interactions. Monomer.

Subcellular location. Cytoplasm.

Tissue specificity. Expressed in kidney (at protein level).

Activity regulation. Inhibited by quercetin, rutenin and its derivatives.

Similarity. Belongs to the short-chain dehydrogenases/reductases (SDR) family.

Isoforms (2)

UniProt ID	Names	Canonical?
P16152-1	1	yes
P16152-2	2

RefSeq proteins (2): NP_001273718, NP_001748* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR002347	SDR_fam	Family
IPR020904	Sc_DH/Rdtase_CS	Conserved_site
IPR036291	NAD(P)-bd_dom_sf	Homologous_superfamily
IPR045313	CBR1-like	Family

Pfam: PF00106

Enzyme classification (BRENDA):

• EC 1.1.1.184 — carbonyl reductase (NADPH) (BRENDA: 40 organisms, 630 substrates, 214 inhibitors, 373 Km, 209 kcat entries)

Substrate kinetics (BRENDA)

114 substrates with measured Km, best-characterized 15. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
MENADIONE	—	31
NADPH	0.0021–10.27	26
2-HYDROXYACETOPHENONE	0.59–10.27	24
4-BENZOYLPYRIDINE	—	19
ISATIN	0.0008–4	19
9,10-PHENANTHRENEQUINONE	0.002–0.078	17
DAUNORUBICIN	0.043–3	13
DOXORUBICIN	0.041–0.335	13
4-NITROBENZALDEHYDE	0.12–1.1	9
NADH	0.062–8.67	9
1,4-NAPHTHOQUINONE	0.0073–0.54	6
PROSTAGLANDIN E2	0.03–0.32	6
2,3-HEXANEDIONE	0.06–0.62	5
ETHYL 4-CHLORO-3-OXOBUTANOATE	0.0026–4.6	5
S-NITROSOGLUTATHIONE	0.028–2.93	5

Catalyzed reactions (Rhea), 12 shown:

• prostaglandin E1 + NADP(+) = 15-oxoprostaglandin E1 + NADPH + H(+) (RHEA:11636)
• a primary alcohol + NADP(+) = an aldehyde + NADPH + H(+) (RHEA:15937)
• a secondary alcohol + NADP(+) = a ketone + NADPH + H(+) (RHEA:19257)
• prostaglandin D2 + NADP(+) = 15-oxoprostaglandin D2 + NADPH + H(+) (RHEA:20744)
• prostaglandin F2alpha + NADP(+) = prostaglandin E2 + NADPH + H(+) (RHEA:24508)
• prostaglandin E2 + NADP(+) = 15-oxoprostaglandin E2 + NADPH + H(+) (RHEA:63476)
• prostaglandin F2alpha + NADP(+) = 15-oxoprostaglandin F2alpha + NADPH + H(+) (RHEA:63480)
• menadione + NADPH + H(+) = menadiol + NADP(+) (RHEA:63492)
• S-nitrosoglutathione + NADPH + H(+) = S-(hydroxysulfenamide)glutathione + NADP(+) (RHEA:63500)
• daunorubicin + NADPH + H(+) = 13-dihydrodaunorubicin + NADP(+) (RHEA:63504)
• cortisol + NADPH + H(+) = 20beta-dihydrocortisol + NADP(+) (RHEA:70215)
• corticosterone + NADPH + H(+) = 20beta-dihydrocorticosterone + NADP(+) (RHEA:70219)

UniProt features (42 total): helix 12, binding site 9, strand 8, modified residue 4, splice variant 2, sequence variant 2, turn 2, initiator methionine 1, chain 1, active site 1

Structure

Experimental structures (PDB)

6 structures.

PDB	Method	Resolution (Å)
1WMA	X-RAY DIFFRACTION	1.24
2PFG	X-RAY DIFFRACTION	1.54
3BHJ	X-RAY DIFFRACTION	1.77
3BHM	X-RAY DIFFRACTION	1.8
4Z3D	X-RAY DIFFRACTION	1.8
3BHI	X-RAY DIFFRACTION	2.27

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P16152-F1	97.88	0.99

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (1): 194 (proton acceptor)

Ligand- & substrate-binding residues (9): 194–198; 231–233; 10–34; 63–64; 90; 95–97; 106; 140; 193–194

Post-translational modifications (4): 2, 2, 30, 239

Function

Pathways and Gene Ontology

Reactome pathways

5 pathways

ID	Pathway
R-HSA-2162123	Synthesis of Prostaglandins (PG) and Thromboxanes (TX)
R-HSA-1430728	Metabolism
R-HSA-2142753	Arachidonate metabolism
R-HSA-556833	Metabolism of lipids
R-HSA-8978868	Fatty acid metabolism

MSigDB gene sets: 241 (showing top): MODULE_93, GOBP_EPITHELIUM_DEVELOPMENT, JI_RESPONSE_TO_FSH_UP, GOBP_GLUCOCORTICOID_METABOLIC_PROCESS, STARK_PREFRONTAL_CORTEX_22Q11_DELETION_DN, GOBP_MONOCARBOXYLIC_ACID_METABOLIC_PROCESS, GOBP_KETONE_METABOLIC_PROCESS, GOBP_ORGANIC_ACID_BIOSYNTHETIC_PROCESS, MODULE_66, SMITH_TERT_TARGETS_DN, GOBP_SMALL_MOLECULE_BIOSYNTHETIC_PROCESS, MODULE_120, ONKEN_UVEAL_MELANOMA_UP, HOSHIDA_LIVER_CANCER_SUBCLASS_S3, GOBP_REGULATION_OF_REACTIVE_OXYGEN_SPECIES_METABOLIC_PROCESS

GO Biological Process (7): xenobiotic metabolic process (GO:0006805), glucocorticoid metabolic process (GO:0008211), epithelial cell differentiation (GO:0030855), vitamin K metabolic process (GO:0042373), prostanoid biosynthetic process (GO:0046457), positive regulation of reactive oxygen species metabolic process (GO:2000379), lipid metabolic process (GO:0006629)

GO Molecular Function (10): carbonyl reductase (NADPH) activity (GO:0004090), oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor (GO:0016616), oxidoreductase activity, acting on NAD(P)H, quinone or similar compound as acceptor (GO:0016655), 15-hydroxyprostaglandin-D dehydrogenase (NADP+) activity (GO:0047020), 15-hydroxyprostaglandin dehydrogenase (NADP+) activity (GO:0047021), prostaglandin E2 9-reductase activity (GO:0050221), S-nitrosoglutathione reductase (NADPH) activity (GO:0160163), protein binding (GO:0005515), alcohol dehydrogenase (NADP+) activity (GO:0008106), oxidoreductase activity (GO:0016491)

GO Cellular Component (4): cytosol (GO:0005829), extracellular exosome (GO:0070062), extracellular vesicle (GO:1903561), cytoplasm (GO:0005737)

Reactome top-level categories

Rollup of top-4 pathways:

Category	Pathways
Arachidonate metabolism	1
Fatty acid metabolism	1
Metabolism	1
Metabolism of lipids	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor	4
cellular anatomical structure	2
metabolic process	1
cellular response to xenobiotic stimulus	1
steroid metabolic process	1
cell differentiation	1
epithelium development	1
ketone metabolic process	1
unsaturated fatty acid biosynthetic process	1
prostanoid metabolic process	1
icosanoid biosynthetic process	1
positive regulation of metabolic process	1
reactive oxygen species metabolic process	1
regulation of reactive oxygen species metabolic process	1
primary metabolic process	1
alcohol dehydrogenase (NADP+) activity	1
oxidoreductase activity, acting on CH-OH group of donors	1
oxidoreductase activity, acting on NAD(P)H	1
binding	1
alcohol dehydrogenase [NAD(P)+] activity	1
catalytic activity	1
cytoplasm	1
extracellular vesicle	1
extracellular region	1
vesicle	1
extracellular membrane-bounded organelle	1
intracellular anatomical structure	1

Protein interactions and networks

STRING

3647 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
CBR1	AKR1B1	P15121	906
CBR1	AKR1A1	P14550	893
CBR1	DHFR2	Q86XF0	802
CBR1	MCEE	Q96PE7	766
CBR1	SPR	P35270	744
CBR1	DHFR	P00374	732
CBR1	AKR1C3	P42330	673
CBR1	AKR1C1	P52896	604
CBR1	CNR1	P21554	591
CBR1	CBR4	Q8N4T8	546
CBR1	AKR7A2	O43488	543
CBR1	AKR1B10	O60218	541
CBR1	PTGS2	P35354	540
CBR1	AKR1C2	P52895	523
CBR1	AKR1C4	P17516	522

IntAct

120 interactions, top by confidence:

A	B	Type	Score
CBR3	CBR1	psi-mi:“MI:0914”(association)	0.710
CFTR	ESYT2	psi-mi:“MI:0914”(association)	0.710
CBR3	CBR1	psi-mi:“MI:0915”(physical association)	0.710
CFTR	HAX1	psi-mi:“MI:0914”(association)	0.610
EGFR	CBR1	psi-mi:“MI:0915”(physical association)	0.550
SSBP2	CLEC18A	psi-mi:“MI:0914”(association)	0.530
CFTR	PLEKHG3	psi-mi:“MI:0914”(association)	0.480
TSC22D1	KRT1	psi-mi:“MI:0914”(association)	0.460
CBR1	GAPDHS	psi-mi:“MI:0915”(physical association)	0.400
CBR1	AGTR1	psi-mi:“MI:0915”(physical association)	0.370
CBR1	HTR2B	psi-mi:“MI:0915”(physical association)	0.370
ERBB2	CBR1	psi-mi:“MI:0915”(physical association)	0.370
OTUB1		psi-mi:“MI:0914”(association)	0.350
OTUB1	EPM2A	psi-mi:“MI:0914”(association)	0.350
CBR3	LDLR	psi-mi:“MI:0914”(association)	0.350
CBR1	DENND3	psi-mi:“MI:0914”(association)	0.350
JUN	TPM3	psi-mi:“MI:0914”(association)	0.350
LACC1	FLJ10842	psi-mi:“MI:0914”(association)	0.350
URM1	ELP1	psi-mi:“MI:0914”(association)	0.350
CUL1	LGALS8	psi-mi:“MI:0914”(association)	0.350

BioGRID (175): CBR1 (Affinity Capture-RNA), CBR1 (Affinity Capture-MS), CBR1 (Co-fractionation), CBR1 (Co-fractionation), RBM12 (Co-fractionation), CBR1 (Affinity Capture-MS), CBR1 (Affinity Capture-MS), MYH1 (Affinity Capture-MS), ICAM5 (Affinity Capture-MS), APBA3 (Affinity Capture-MS), ZNF518A (Affinity Capture-MS), TXNL4A (Affinity Capture-MS), SEC61B (Affinity Capture-MS), DENND3 (Affinity Capture-MS), NCBP2 (Affinity Capture-MS)

ESM2 similar proteins: B2GV54, D3K5L7, E2R222, O60656, O95803, P16152, P52848, Q08DW9, Q0VCJ8, Q0VD27, Q15645, Q1JQE6, Q2HJ19, Q3U129, Q3UA06, Q3UHN9, Q4R766, Q5E9T4, Q5R8Y5, Q5RCU5, Q5XHZ9, Q5XIJ5, Q5ZIN0, Q5ZMH6, Q67FW5, Q6AYT7, Q6DD70, Q6GL10, Q6GV29, Q6PIU2, Q8BGB7, Q8BK26, Q8BLF1, Q8BWB6, Q8MI29, Q8N2K0, Q8NFT2, Q8VDI9, Q99JW1, Q99LR1

Diamond homologs: A0A017SEY2, A0A023I4F1, A0A078IS66, A0A078ISJ6, A0A0U1LQE2, A0A0U5CNP2, A0A1B7YCL6, A0A1V0QS34, A0A1V6PAN1, A0A223HDI5, A0A2H3CNT9, A0A2H3D905, A0A443HJZ3, A0A482ND39, A0A823A767, A0PJE2, A2RVM0, A6QP05, B2X050, B6H062, B8A5W4, C8VI80, D7UTD0, G1XTZ5, I1RL15, O32291, O74959, P0DXW2, P16152, P19871, P21218, P35320, P40747, P47727, P50163, P51657, P59837, Q01289, Q03326, Q08651

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 139 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

GO biological processes:

GO term	Partners	Fold	FDR
negative regulation of gene expression	10	5.4×	6e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

67 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	2
Likely pathogenic	0
Uncertain significance	52
Likely benign	3
Benign	1

Top pathogenic / likely-pathogenic (2)

Variant ID	HGVS	Classification
3248151	NC_000021.8:g.(?36164432)(37834775_?)del	Pathogenic
812918	NC_000021.8:g.36323351_37470324del	Pathogenic

SpliceAI

439 predictions. Top by Δscore:

Variant	Effect	Δscore
21:36070352:G:GT	donor_gain	1.0000
21:36070352:GGA:G	donor_gain	1.0000
21:36070353:G:GT	donor_gain	1.0000
21:36070355:G:GG	donor_gain	1.0000
21:36070368:G:GT	donor_gain	1.0000
21:36070403:GG:G	donor_gain	1.0000
21:36070404:GGTA:G	donor_gain	1.0000
21:36070945:A:AG	acceptor_gain	1.0000
21:36070946:A:G	acceptor_gain	1.0000
21:36070946:AAAGT:A	acceptor_loss	1.0000
21:36070947:AAGTT:A	acceptor_gain	1.0000
21:36070948:A:AG	acceptor_gain	1.0000
21:36070948:AGT:A	acceptor_loss	1.0000
21:36070949:G:GG	acceptor_gain	1.0000
21:36070949:G:GT	acceptor_loss	1.0000
21:36070949:GTT:G	acceptor_gain	1.0000
21:36071054:CAAGG:C	donor_loss	1.0000
21:36071055:AAGGT:A	donor_loss	1.0000
21:36071056:AGGTG:A	donor_loss	1.0000
21:36071058:G:GC	donor_loss	1.0000
21:36071059:T:A	donor_loss	1.0000
21:36070353:GA:G	donor_gain	0.9900
21:36070402:AGG:A	donor_gain	0.9900
21:36070403:GGG:G	donor_gain	0.9900
21:36070405:G:GG	donor_gain	0.9900
21:36070405:GTAT:G	donor_loss	0.9900
21:36070406:T:A	donor_loss	0.9900
21:36070947:A:AG	acceptor_gain	0.9900
21:36070948:AGTT:A	acceptor_gain	0.9900
21:36070949:GTTG:G	acceptor_gain	0.9900

AlphaMissense

1807 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
21:36072628:T:C	Y194H	0.994
21:36070382:C:A	N89K	0.993
21:36070382:C:G	N89K	0.993
21:36071002:T:A	N114K	0.993
21:36071002:T:G	N114K	0.993
21:36072466:A:C	S140R	0.993
21:36072468:C:A	S140R	0.993
21:36072468:C:G	S140R	0.993
21:36072613:T:A	W189R	0.993
21:36072613:T:C	W189R	0.993
21:36072642:G:C	K198N	0.992
21:36072642:G:T	K198N	0.992
21:36072475:A:C	S143R	0.990
21:36072477:C:A	S143R	0.990
21:36072477:C:G	S143R	0.990
21:36072571:T:C	F175L	0.990
21:36072573:T:A	F175L	0.990
21:36072573:T:G	F175L	0.990
21:36072726:C:G	C226W	0.990
21:36072641:A:C	K198T	0.989
21:36072459:C:A	N137K	0.988
21:36072459:C:G	N137K	0.988
21:36072467:G:T	S140I	0.988
21:36072720:T:A	N224K	0.988
21:36072720:T:G	N224K	0.988
21:36072736:T:A	W230R	0.988
21:36072736:T:C	W230R	0.988
21:36072746:C:T	T233I	0.988
21:36070161:G:C	G16R	0.987
21:36070398:T:C	F95L	0.987

dbSNP variants (sampled 300 via entrez): RS1000335693 (21:36070386 G>A), RS1000643873 (21:36071386 T>C,G), RS1000673305 (21:36071663 A>G), RS1000857332 (21:36073350 T>A), RS1002191556 (21:36071189 G>C), RS1002919189 (21:36071741 C>G), RS1003202795 (21:36069888 C>G), RS1003256032 (21:36070369 A>T), RS1003841480 (21:36068613 G>A,C), RS1005000177 (21:36069072 G>C), RS1005111 (21:36071683 T>A), RS1005694 (21:36071360 T>A,C,G), RS1005695 (21:36071267 G>A,C), RS1005696 (21:36071182 T>C,G), RS1006360426 (21:36071444 C>T)

Disease associations

OMIM: gene MIM:114830 | disease phenotypes: MIM:601399, MIM:614104

GenCC curated gene-disease

Mondo (3): hereditary thrombocytopenia and hematological cancer predisposition syndrome associated with RUNX1 (MONDO:0100083), DYRK1A-related intellectual disability syndrome (MONDO:0013578), thrombocytopenia (MONDO:0002049)

Orphanet (2): Familial platelet disorder with associated myeloid malignancy (Orphanet:71290), DYRK1A-related intellectual disability syndrome (Orphanet:464306)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

4 associations (top):

Study	Trait	p-value
GCST003094_3	Mitral valve prolapse	1.000000e-08
GCST006585_568	Blood protein levels	2.000000e-24
GCST009391_1115	Metabolite levels	9.000000e-06
GCST009391_985	Metabolite levels	8.000000e-07

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0010448	3-hydroxyphenylacetic acid measurement
EFO:0010475	deoxycholate measurement

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D013921	Thrombocytopenia	C15.378.140.855; C15.378.243.937

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL5586 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

1 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 77,720 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL849	TRICLOSAN	4	77,720

PharmGKB: 1 entry (VIP=true, CPIC=false)

PharmGKB clinical annotations

4 annotations.

Variant	Type	Level	Drugs	Phenotypes
rs20572	Metabolism/PK	3	doxorubicin;doxorubicinol	Breast Neoplasms
rs20572	Toxicity	3	cyclophosphamide;doxorubicin;fluorouracil	Breast Neoplasms
rs9024	Dosage,Metabolism/PK	3	doxorubicin	Breast Neoplasms
rs9024	Toxicity	3	anthracyclines and related substances	Cardiomyopathies;Neoplasms

PharmGKB variants

7 variants.

Variant	Genes	Level	Score	#Clin annots	Drugs
rs9024	CBR1, SETD4	3	5.75	2	anthracyclines and related substances;doxorubicin
rs20572	CBR1, SETD4	3	3.50	2	cyclophosphamide;doxorubicin;fluorouracil;doxorubicin;doxorubicinol
rs1143663	CBR1, SETD4		0.00	0
rs41557318	CBR1, SETD4		0.00	0
rs25678	CBR1		0.00	0
rs3787728	CBR1		0.00	0
rs1005695	CBR1		0.00	0

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: enzyme — Prostaglandin synthases

Most potent curated ligand interactions (1 total), top 1:

Ligand	Action	Affinity	Parameter
wedelolactone	Inhibition	5.42	pIC50

ChEMBL bioactivities

29 potent at pChembl≥5 of 35 total, top 29 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
7.47	IC50	34	nM	CHEMBL4640248
7.40	Ki	40	nM	CHEMBL453375
7.22	Ki	60	nM	TRICLOSAN
7.12	IC50	75	nM	CHEMBL4640154
6.96	Ki	110	nM	CHRYSIN
6.92	IC50	120	nM	CHEMBL4639417
6.83	Kd	146.3	nM	CHEMBL5653589
6.83	ED50	146.3	nM	CHEMBL5653589
6.68	IC50	210	nM	CHEMBL453375
6.60	IC50	250	nM	CHEMBL4646593
6.57	IC50	270	nM	CHEMBL4648793
6.43	IC50	370	nM	CHEMBL4634960
6.40	IC50	400	nM	TRICLOSAN
6.36	IC50	440	nM	CHEMBL4644092
6.28	Ki	520	nM	RADICICOL
6.22	Ki	600	nM	WEDELOLACTONE
6.17	IC50	670	nM	CHRYSIN
6.12	IC50	759	nM	CHEMBL590508
6.10	IC50	788	nM	CHEMBL590508
5.96	IC50	1100	nM	CHEMBL4089817
5.69	Ki	2030	nM	BIOCHANIN
5.52	IC50	3000	nM	CHEMBL601512
5.49	IC50	3270	nM	RADICICOL
5.46	Ki	3430	nM	NARINGENIN
5.42	IC50	3780	nM	WEDELOLACTONE
5.40	IC50	4000	nM	CHEMBL603058
5.40	IC50	4000	nM	CHEMBL589095
5.38	IC50	4200	nM	CHEMBL4081954
5.30	IC50	5000	nM	CHEMBL591062

PubChem BioAssay actives

28 with measured affinity, of 141 total; 22 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
N-(2-chlorophenyl)-8-hydroxy-2-iminochromene-3-carboxamide	1661956: Inhibition of CBR1 (unknown origin)	ic50	0.0340	uM
(4S,9S,12E)-16,18-dihydroxy-4,9-dimethyl-3-oxabicyclo[12.4.0]octadeca-1(14),12,15,17-tetraene-2,8-dione	347259: Binding affinity to human recombinant carbonyl reductase 1 expressed in Escherichia coli assessed as NADPH oxidation using isatin as substrate	ki	0.0400	uM
Triclosan	347259: Binding affinity to human recombinant carbonyl reductase 1 expressed in Escherichia coli assessed as NADPH oxidation using isatin as substrate	ki	0.0600	uM
8-hydroxy-2-imino-N-[2-(trifluoromethyl)phenyl]chromene-3-carboxamide	1661956: Inhibition of CBR1 (unknown origin)	ic50	0.0750	uM
5,7-dihydroxy-2-phenylchromen-4-one	347259: Binding affinity to human recombinant carbonyl reductase 1 expressed in Escherichia coli assessed as NADPH oxidation using isatin as substrate	ki	0.1100	uM
N-(3-chlorophenyl)-8-hydroxy-2-iminochromene-3-carboxamide	1661956: Inhibition of CBR1 (unknown origin)	ic50	0.1200	uM
4-methyl-3-[(2-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide	2148002: Binding affinity to human CBR1 incubated for 45 mins by Kinobead based pull down assay	kd	0.1463	uM
N-(3-ethylphenyl)-8-hydroxy-2-iminochromene-3-carboxamide	1661956: Inhibition of CBR1 (unknown origin)	ic50	0.2500	uM
8-hydroxy-2-imino-N-(4-methylphenyl)chromene-3-carboxamide	1661956: Inhibition of CBR1 (unknown origin)	ic50	0.2700	uM
N-(3-fluorophenyl)-8-hydroxy-2-iminochromene-3-carboxamide	1661956: Inhibition of CBR1 (unknown origin)	ic50	0.3700	uM
N-(4-fluorophenyl)-8-hydroxy-2-iminochromene-3-carboxamide	1661956: Inhibition of CBR1 (unknown origin)	ic50	0.4400	uM
(4R,6R,8R,9Z,11E)-16-chloro-17,19-dihydroxy-4-methyl-3,7-dioxatricyclo[13.4.0.06,8]nonadeca-1(15),9,11,16,18-pentaene-2,13-dione	347259: Binding affinity to human recombinant carbonyl reductase 1 expressed in Escherichia coli assessed as NADPH oxidation using isatin as substrate	ki	0.5200	uM
1,8,9-trihydroxy-3-methoxy-[1]benzofuro[3,2-c]chromen-6-one	347259: Binding affinity to human recombinant carbonyl reductase 1 expressed in Escherichia coli assessed as NADPH oxidation using isatin as substrate	ki	0.6000	uM
3-(4-amino-1-tert-butyl-2,3-dihydropyrazolo[3,4-d]pyrimidin-3-yl)phenol	456708: Inhibition of CBR-mediated NADPH-dependent reduction of menadione to menadiol	ic50	0.7590	uM
N-[3-(4-fluorophenyl)propyl]-7-hydroxy-2-oxochromene-3-carboxamide	1465667: Inhibition of recombinant human CBR1 using isatin as substrate	ic50	1.1000	uM
5,7-dihydroxy-3-(4-methoxyphenyl)chromen-4-one	347259: Binding affinity to human recombinant carbonyl reductase 1 expressed in Escherichia coli assessed as NADPH oxidation using isatin as substrate	ki	2.0300	uM
methyl N-[2-(5-hydroxy-4,9-dioxo-2H-benzo[f]indazol-3-yl)ethyl]carbamate	456712: Displacement of menadione from human recombinant CBR expressed in Escherichia coli BL21 (DE3)	ic50	3.0000	uM
(2S)-5,7-dihydroxy-2-(4-hydroxyphenyl)-2,3-dihydrochromen-4-one	347259: Binding affinity to human recombinant carbonyl reductase 1 expressed in Escherichia coli assessed as NADPH oxidation using isatin as substrate	ki	3.4300	uM
methyl N-[2-[6-(N-ethylanilino)-4,7-dioxo-2H-indazol-3-yl]ethyl]carbamate	456712: Displacement of menadione from human recombinant CBR expressed in Escherichia coli BL21 (DE3)	ic50	4.0000	uM
methyl N-[2-[6-(N-methylanilino)-4,7-dioxo-2H-indazol-3-yl]ethyl]carbamate	456712: Displacement of menadione from human recombinant CBR expressed in Escherichia coli BL21 (DE3)	ic50	4.0000	uM
7-hydroxy-N-[3-(4-hydroxyphenyl)propyl]-2-oxochromene-3-carboxamide	1465667: Inhibition of recombinant human CBR1 using isatin as substrate	ic50	4.2000	uM
methyl N-[2-(6,7-dichloro-5,8-dimethoxy-4,9-dioxo-2H-benzo[f]indazol-3-yl)ethyl]carbamate	456712: Displacement of menadione from human recombinant CBR expressed in Escherichia coli BL21 (DE3)	ic50	5.0000	uM

CTD chemical–gene interactions

106 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Daunorubicin	increases chemical synthesis, decreases activity, increases metabolic processing, affects binding, decreases reduction (+4 more)	6
Valproic Acid	affects cotreatment, increases expression, affects expression, decreases methylation	6
sodium arsenite	affects cotreatment, increases abundance, increases expression, decreases expression	5
Tobacco Smoke Pollution	increases expression, affects expression, decreases expression	5
Doxorubicin	decreases metabolic processing, affects reduction, increases reduction, increases expression, affects response to substance (+1 more)	4
9,10-phenanthrenequinone	increases metabolic processing, affects binding, increases reaction, affects activity, affects cotreatment (+1 more)	3
2,3-hexanedione	increases reduction, affects binding, increases metabolic processing, decreases reaction	3
NADP	decreases reaction, increases activity, affects activity, affects cotreatment, increases reduction (+1 more)	3
Quercetin	increases reduction, affects binding, decreases activity, affects cotreatment, decreases reaction (+1 more)	3
Cyclosporine	affects cotreatment, decreases expression	3
beta-Naphthoflavone	increases expression	3
Vitamin K 3	increases metabolic processing, affects binding, decreases reaction	3
daunorubicinol	decreases chemical synthesis, decreases reduction, increases chemical synthesis, increases reduction, increases metabolic processing (+2 more)	2
arsenite	affects binding, increases reaction, increases abundance, increases expression	2
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression, increases expression	2
isoxanthohumol	increases metabolic processing, increases reduction, decreases activity, decreases reaction	2
Resveratrol	affects response to substance, decreases activity, affects binding, decreases reaction, increases expression	2
Acetaminophen	decreases expression	2
Aerosols	affects expression, increases expression	2
Benzo(a)pyrene	decreases methylation, increases expression	2
Rutin	affects binding, decreases activity, decreases reaction, increases metabolic processing	2
Smoke	decreases expression, increases expression	2
Genistein	affects binding, affects cotreatment, increases expression	2
S-Nitrosoglutathione	increases reduction, decreases reaction, affects binding, decreases activity, increases activity (+2 more)	2
aristolochic acid I	increases expression	1
frangulin A	decreases activity	1
GSK-J4	decreases expression	1
FR900359	increases phosphorylation	1
bisphenol F	increases expression	1
testosterone enanthate	affects expression	1

ChEMBL screening assays

35 unique, capped per target: 28 binding, 7 admet

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL1004498	Binding	Binding affinity to human recombinant carbonyl reductase 1 expressed in Escherichia coli assessed as thermal shift by differential scanning fluorimetry in absence of cofactor	Discovery of a potent and selective inhibitor for human carbonyl reductase 1 from propionate scanning applied to the macrolide zearalenone. — Bioorg Med Chem
CHEMBL3532631	ADMET	Activity of carbonyl reductase in liver cytosol (unknown origin) assessed as enzyme-mediated drug metabolism	Significance of reductive metabolism in human intestine and quantitative prediction of intestinal first-pass metabolism by cytosolic reductive enzymes. — Drug Metab Dispos

Cellosaurus cell lines

5 cell lines: 5 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B2M9	Abcam A-549 CBR1 KO	Cancer cell line	Male
CVCL_E1T2	HAP1 CBR1 (-) 1	Cancer cell line	Male
CVCL_E1T3	HAP1 CBR1 (-) 2	Cancer cell line	Male
CVCL_E1T4	HAP1 CBR1 (-) 3	Cancer cell line	Male
CVCL_E1T5	HAP1 CBR1 (-) 4	Cancer cell line	Male

Clinical trials (associated diseases)

241 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00039858	PHASE4	COMPLETED	Evaluation of Argatroban Injection in Pediatric Patients Requiring Anticoagulant Alternatives to Heparin
NCT00239733	PHASE4	TERMINATED	Anti-D for Treating Thrombocytopenia in Adults Infected With Hepatitis C Virus With or Without HIV Co-Infection
NCT00907478	PHASE4	COMPLETED	Study on Bone Marrow Morphology in Adults Receiving Romiplostim for Treatment of Thrombocytopenia Associated With Immune Thrombocytopenia Purpura (ITP)
NCT01727401	PHASE4	TERMINATED	Thromboprophylaxis of Venous Thromboembolism in Acutely-ill Medical Inpatients With Thrombocytopenia
NCT02032134	PHASE4	TERMINATED	Protocol for the Infusion of Buffy Coat-derived Cryopreserved Platelets in Patients With Severe Thrombocytopenia
NCT02267993	PHASE4	COMPLETED	Efficacy and Safety of rhTPO for the Treatment of Thrombocytopenia After Chemotherapy in AML Patients
NCT03633019	PHASE4	UNKNOWN	High-dose Use of rhTPO in CIT Patients
NCT03688191	PHASE4	UNKNOWN	Study of Sirolimus in CTD-TP in China
NCT04906083	PHASE4	UNKNOWN	Avatrombopag in Patients With End-stage Liver Disease and Thrombocytopenia
NCT05217719	PHASE4	UNKNOWN	Effects of Recombinant Human Thrombopoietin on Platelet Levels in ICU Patients
NCT05255003	PHASE4	RECRUITING	STrategies for Anticoagulation in Patients With thRombocytopenia and Cancer-associated Thrombosis
NCT05382013	PHASE4	UNKNOWN	Efficacy and Safety of Avatrombopag for Treating TCP in HBV-ACLF Patients Receiving ALSS Treatment
NCT05944458	PHASE4	COMPLETED	Efficacy of Intravenous N-Acetylcysteine in Preventing Linezolid-Induced Thrombocytopenia in Critically Ill Patients
NCT06562738	PHASE4	RECRUITING	Clinical Study on Efficacy and Safety of Hetrombopag in the Preoperative Patients of Thrombocytopenia
NCT00037791	PHASE3	COMPLETED	Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia
NCT00039910	PHASE3	COMPLETED	Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia
NCT00073580	PHASE3	COMPLETED	Angiomax in Patients With HIT/HITTS Type II Undergoing Off-Pump Coronary Artery Bypass Grafting (CABG) (CHOOSE)
NCT00102323	PHASE3	COMPLETED	AMG 531 Treatment of Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Refractory to Splenectomy
NCT00102336	PHASE3	COMPLETED	AMG 531 Treatment of Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Prior to Splenectomy
NCT00116688	PHASE3	COMPLETED	Open Label Extension Study of Romiplostim (AMG 531) in Thrombocytopenic Patients With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
NCT00128713	PHASE3	COMPLETED	Optimal Platelet Dose Strategy for Management of Thrombocytopenia
NCT00151866	PHASE3	COMPLETED	Efficacy of Transfusions With Platelets Stored in Platelet Additive Solution II Versus Plasma
NCT00261924	PHASE3	COMPLETED	Efficacy and Safety Study of Platelets Treated for Pathogen Inactivation and Stored for Up to Seven Days
NCT00415532	PHASE3	COMPLETED	Romiplostim (AMG 531) Versus Medical Standard of Care for Immune (Idiopathic) Thrombocytopenic Purpura
NCT00420914	PHASE3	TERMINATED	Strategies for Transfusion of Platelets (SToP)
NCT00501345	PHASE3	TERMINATED	Aspirin in Patients With Myocardial Infarction and Thrombocytopenia
NCT00508820	PHASE3	COMPLETED	An Open Label Study of Romiplostim in Adult Thrombocytopenic Subjects With ITP
NCT00678587	PHASE3	TERMINATED	Eltrombopag To Reduce The Need For Platelet Transfusion In Subjects With Chronic Liver Disease And Thrombocytopenia Undergoing Elective Invasive Procedures
NCT01438840	PHASE3	COMPLETED	Efficacy and Safety of Oral E5501 Plus Standard of Care for the Treatment of Thrombocytopenia in Adults With Chronic Immune Thrombocytopenia (Amendment 02)
NCT01444417	PHASE3	COMPLETED	Safety and Efficacy Study of Romiplostim to Treat Immune Thrombocytopenia (ITP) in Pediatric Patients
NCT01805648	PHASE3	UNKNOWN	Efficacy and Safety Study of Maintenance Treatment With rhTPO in Thrombocytopenic Subjects With ITP
NCT02244658	PHASE3	UNKNOWN	Recombinant Human Thrombopoietin (rhTPO) in Management of Chemotherapy-induced Thrombocytopenia in Acute Myelocytic Leukemia
NCT02389621	PHASE3	COMPLETED	Safety and Efficacy Study of Lusutrombopag for Thrombocytopenia in Patients With Chronic Liver Disease Undergoing Elective Invasive Procedures
NCT02444728	PHASE3	TERMINATED	Cyclophosphamide and Hydroxychloroquine for Thrombocytopenia in SLE
NCT02487563	PHASE3	COMPLETED	Prospective Study of Patients With Thrombocytopenia Following HSCT
NCT02578901	PHASE3	COMPLETED	American Trial Using Tranexamic Acid in Thrombocytopenia
NCT03326843	PHASE3	TERMINATED	Avatrombopag for the Treatment of Thrombocytopenia in Adults Scheduled for a Surgical Procedure
NCT03515096	PHASE3	COMPLETED	Eltrombopag vs. rhTPO to Increase Platelet Level After HSCT
NCT05563064	PHASE3	UNKNOWN	Effect of Herbal Formulation on Thrombocytes Count
NCT07442513	PHASE3	RECRUITING	Comparison of Etamsylate Versus Placebo to Prevent Bleeding in HSCT